Cyprotex (LSE:CRX) Gross-Profit-to-Asset % : 84.67% (As of Jun. 2016)

View and export this data going back to 2002. Start your Free Trial

What is Cyprotex Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Cyprotex's annualized Gross Profit for the quarter that ended in Jun. 2016 was £13.53 Mil. Cyprotex's average Total Assets over the quarter that ended in Jun. 2016 was £15.98 Mil. Therefore, Cyprotex's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2016 was 84.67%.

Cyprotex Gross-Profit-to-Asset % Historical Data

The historical data trend for Cyprotex's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex Gross-Profit-to-Asset % Chart

Cyprotex Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

74.23

72.05

57.68

56.84

84.59

Cyprotex Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															49.17	58.65	80.19	93.15	84.67

Competitive Comparison of Cyprotex's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Cyprotex's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyprotex's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyprotex's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Cyprotex's Gross-Profit-to-Asset % falls into.

Cyprotex Gross-Profit-to-Asset % Calculation

Cyprotex's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2015 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2015 )	/	( (Total Assets (A: Dec. 2014 )	+	Total Assets (A: Dec. 2015 ))	/ count )
	=	12.059	/	( (13.044	+	15.466)	/ 2 )
	=	12.059	/	14.255
	=	84.59 %

Cyprotex's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2016 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2016 )	/	( (Total Assets (Q: Dec. 2015 )	+	Total Assets (Q: Jun. 2016 ))	/ count )
	=	13.53	/	( (15.466	+	16.492)	/ 2 )
	=	13.53	/	15.979
	=	84.67 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2016) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Cyprotex Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Cyprotex's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyprotex (LSE:CRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (LSE:CRX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cyprotex.com

Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (LSE:CRX) Headlines

No Headlines